Pancreatic Cancer Research

ResearcherJikei University School of MedicineNo recent work listed

Hiroaki Shiba

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0688-2078; OpenAlex author ID A5102960015. Sources: OpenAlex.

Their work

Papers
29 (first author 10, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 4 papers · 2014: 1 paper · 2015: 3 papers · 2016: 3 papers · 2017: 2 papers · 2018: 4 papers · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers

Papers 29

  1. The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8th edition. Co-author DOI 10.1007/s00423-022-02686-3↗
  2. Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer. Co-author DOI 10.1371/journal.pone.0267623↗
  3. The novel index using preoperative C-reactive protein and neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.1007/s10147-021-01964-2↗
  4. Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001767↗
  5. Splenic artery pseudoaneurysm following chemotherapy in a patient with pancreatic cancer: a case report. First author DOI 10.1007/s12328-020-01137-0↗
  6. Prognostic Factors in Patients With Recurrent Pancreatic Cancer: A Multicenter Database Analysis. First author DOI 10.21873/anticanres.13952↗
  7. Incidental abdominal lymph node metastases from a known breast cancer in resected specimen of invasive pancreatic ductal adenocarcinoma: report of a case. Co-author DOI 10.1007/s13691-019-00382-6↗
  8. Combination of Distance from Superior Mesenteric Artery and Serum CA19-9 as a Novel Prediction of Local Recurrence in Patients With Pancreatic Cancer Following… Co-author DOI 10.21873/anticanres.13264↗
  9. Glycogen synthase kinase-3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells. First author DOI 10.1002/ags3.12025↗
  10. Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB. Co-author DOI 10.18632/oncotarget.24577↗
  11. Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo. Co-author DOI 10.18632/oncotarget.24608↗
  12. C-Reactive Protein-based Prognostic Measures Are Superior at Predicting Survival Compared with Peripheral Blood Cell Count-based Ones in Patients After Curativ… Co-author DOI 10.21873/anticanres.13013↗
  13. Recombinant thrombomodulin suppresses tumor growth of pancreatic cancer by blocking thrombin-induced PAR1 and NF-κB activation. Co-author DOI 10.1016/j.surg.2016.12.008↗
  14. Preoperative Platelet-to-Albumin Ratio Predicts Prognosis of Patients with Pancreatic Ductal Adenocarcinoma After Pancreatic Resection. First author DOI 10.21873/anticanres.11378↗
  15. The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection. First author DOI 10.1007/s00268-016-3491-4↗
  16. Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer. First author DOI 10.1016/j.canlet.2015.10.034↗
  17. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer. Co-author DOI 10.1016/j.jss.2016.06.047↗
  18. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. First author DOI 10.1016/j.surg.2015.03.043↗
  19. Radical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a Ca… First author DOI 10.9738/intsurg-d-13-00193.1↗
  20. Negative Impact of Preoperative Endoscopic Biliary Drainage on Prognosis of Pancreatic Ductal Adenocarcinoma After Pancreaticoduodenectomy. First author PMID 26254410↗
  21. Postoperative peripheral absolute blood lymphocyte-to-monocyte ratio predicts therapeutic outcome after pancreatic resection in patients with pancreatic adenoc… Co-author PMID 25202109↗
  22. Nuclear factor κB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model. Co-author DOI 10.1007/s00595-012-0279-5↗
  23. Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for p… First author DOI 10.1016/j.jamcollsurg.2012.09.016↗
  24. Erlotinib-induced thrombocytosis in patients with recurrence of pancreatic cancer after distal pancreatectomy. Co-author DOI 10.1097/mpa.0b013e31828cf976↗
  25. Negative impact of fresh-frozen plasma transfusion on prognosis of pancreatic ductal adenocarcinoma after pancreatic resection. Co-author PMID 24023348↗
  26. Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy. Co-author PMID 23155291↗
  27. Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition. Co-author DOI 10.1007/s00534-011-0390-9↗
  28. Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice. Co-author DOI 10.1016/j.canlet.2011.02.036↗
  29. Combination paclitaxel and inhibitor of nuclear factor κB activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic ca… Co-author DOI 10.1097/mpa.0b013e31820b9257↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Katsuhiko K. Yanaga · 27 shared papers, 2011–2022 · strength 1.85
  2. Koichiro Haruki · 22 shared papers, 2011–2022 · strength 1.50
  3. Kenei Furukawa · 20 shared papers, 2011–2022 · strength 1.40
  4. Yoshihiro Shirai · 16 shared papers, 2014–2022 · strength 1.33
  5. Yuki Fujiwara · 20 shared papers, 2011–2022 · strength 1.16
  6. Tadashi Uwagawa · 15 shared papers, 2011–2018 · strength 0.78
  7. Ryoga Hamura · 6 shared papers, 2018–2022 · strength 0.70
  8. Takeshi Gocho · 6 shared papers, 2012–2022 · strength 0.65
  9. Taro Sakamoto · 6 shared papers, 2015–2022 · strength 0.62
  10. Takashi Horiuchi · 9 shared papers, 2015–2018 · strength 0.60
  11. Shinji Onda · 4 shared papers, 2021–2022 · strength 0.54
  12. Tadashi Uwagawa · 3 shared papers, 2021–2022 · strength 0.41
  13. Toru Ikegami · 3 shared papers, 2021–2022 · strength 0.40
  14. Nobuhiro Saito · 5 shared papers, 2016–2018 · strength 0.36
  15. Tomohiko Taniai · 2 shared papers, 2019–2021 · strength 0.24
  16. Masayuki Saruta · 1 shared paper, 2020 · strength 0.13
  17. Hironori Shiozaki · 1 shared paper, 2021 · strength 0.13
  18. Masashi Tsunematsu · 1 shared paper, 2022 · strength 0.13
  19. Shuichi Fujioka · 1 shared paper, 2022 · strength 0.13
  20. Mitsuru Yanagaki · 1 shared paper, 2021 · strength 0.12
  21. Michinori Matsumoto · 1 shared paper, 2019 · strength 0.11
  22. Fumitake Suzuki · 1 shared paper, 2019 · strength 0.11
  23. Hiroshi Sugano · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.